HOTH

Hoth Therapeutics (HOTH)

Hoth Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:HOTH

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/15	05 : 00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:HOTH	Hoth Therapeutics Inc
2024/05/01	21 : 00	PR Newswire (US)	Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024	NASDAQ:HOTH	Hoth Therapeutics Inc
2024/03/28	03 : 00	PR Newswire (US)	Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds	NASDAQ:HOTH	Hoth Therapeutics Inc
2024/03/27	21 : 27	PR Newswire (US)	Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment	NASDAQ:HOTH	Hoth Therapeutics Inc
2024/03/19	21 : 21	PR Newswire (US)	Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ	NASDAQ:HOTH	Hoth Therapeutics Inc
2024/02/29	22 : 38	PR Newswire (US)	Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio	NASDAQ:HOTH	Hoth Therapeutics Inc
2024/02/26	22 : 11	PR Newswire (US)	Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic	NASDAQ:HOTH	Hoth Therapeutics Inc
2024/02/14	01 : 45	PR Newswire (US)	Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024	NASDAQ:HOTH	Hoth Therapeutics Inc
2024/01/18	22 : 20	PR Newswire (US)	Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients	NASDAQ:HOTH	Hoth Therapeutics Inc
2024/01/10	05 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HOTH	Hoth Therapeutics Inc
2024/01/09	07 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HOTH	Hoth Therapeutics Inc
2024/01/09	07 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HOTH	Hoth Therapeutics Inc
2024/01/09	07 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HOTH	Hoth Therapeutics Inc
2024/01/09	07 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/12/27	22 : 21	PR Newswire (US)	Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/12/05	22 : 33	PR Newswire (US)	Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/11/14	22 : 37	PR Newswire (US)	Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/11/14	06 : 16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/11/10	22 : 00	PR Newswire (US)	Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/10/05	23 : 03	PR Newswire (US)	Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/10/05	21 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/10/02	21 : 33	PR Newswire (US)	FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/09/16	05 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/09/16	03 : 38	PR Newswire (US)	Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/09/15	06 : 24	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/09/14	02 : 43	PR Newswire (US)	Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/09/13	21 : 16	PR Newswire (US)	Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/09/11	23 : 04	PR Newswire (US)	Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/09/06	21 : 12	PR Newswire (US)	Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa	NASDAQ:HOTH	Hoth Therapeutics Inc
2023/08/22	06 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HOTH	Hoth Therapeutics Inc